CN Patent

CN101679356A — 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型

Assigned to Pfizer Products Inc · Expires 2010-03-24 · 16y expired

What this patent protects

本发明涉及6－[2－(甲基氨甲酰基)苯基硫基]－3－E－[2－(吡啶－2－基)乙烯基]吲唑的结晶多晶型及非晶形形式以及其制备方法。本发明亦涉及含有至少一种多晶型的药物组合物以及该多晶型及组合物的治疗或预防用途。

USPTO Abstract

本发明涉及6－[2－(甲基氨甲酰基)苯基硫基]－3－E－[2－(吡啶－2－基)乙烯基]吲唑的结晶多晶型及非晶形形式以及其制备方法。本发明亦涉及含有至少一种多晶型的药物组合物以及该多晶型及组合物的治疗或预防用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN101679356A
Jurisdiction
CN
Classification
—
Expires
2010-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.